Identification of novel targets and drug candidates against multi-drug resistant bacteria

Fonte Standard Gras
Identifiant

Unité de recherche

INNOSUISSE

Numéro de projet

11601.1;8 PFLS-LS

Titre du projet

Identification of novel targets and drug candidates against multi-drug resistant bacteria

Titre du projet anglais

Identification of novel targets and drug candidates against multi-drug resistant bacteria

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Description succincte	-	-	-
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Description succincte (Anglais)	Identification of novel targets and drug candidates against multi-drug resistant bacteria
Résumé des résultats (Abstract) (Anglais)	This project approaches the increasing problem of multi-resistant, pathogenic bacterial strains with a novel and unique intervention strategy. Following a top-down approach, newly identified potential transcriptional resistance regulators from clinical isolates will be integrated into our multilevel discovery and development process consisting of deep sequencing (identification of resistance gene clusters), molecular characterization, TRIC screening (in vitro, in pathogen and in mammalian cells) and rational compound design. This will lead to the development of small drug-like compounds that allow for reactivation of licensed antibiotics.

Catégorie

Texte

Description succincte
(Anglais)

Identification of novel targets and drug candidates against multi-drug resistant bacteria

Résumé des résultats (Abstract)
(Anglais)

This project approaches the increasing problem of multi-resistant, pathogenic bacterial strains with a novel and unique intervention strategy. Following a top-down approach, newly identified potential transcriptional resistance regulators from clinical isolates will be integrated into our multilevel discovery and development process consisting of deep sequencing (identification of resistance gene clusters), molecular characterization, TRIC screening (in vitro, in pathogen and in mammalian cells) and rational compound design. This will lead to the development of small drug-like compounds that allow for reactivation of licensed antibiotics.